Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adagloxad simolenin - OBI Pharma

Drug Profile

Adagloxad simolenin - OBI Pharma

Alternative Names: Adagloxad simolenin; Cancer vaccine Globo-H; Globo H-KLH; Globo-H vaccine; OBI 822; OBI-822/OBI-821; OPT-22; OPT-822/821; OPT-822/OPT-821

Latest Information Update: 14 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer OBI Pharma
  • Class Cancer vaccines; Conjugate-vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 10 Aug 2018 Chang Gung Memorial Hospital plans a phase II trial for Hepatocellular carcinoma (First-line therapy, Combination therapy, Adjuvant therapy) in Taiwan (NCT03608878)
  • 04 Jun 2016 Efficacy data from a phase II/III trial in Brest cancer presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
  • 22 Feb 2016 OBI Pharma plans a phase III trial for Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top